Micronization is a critical form of particle engineering that acts as the essential bridge where a Drug Substance (API) is modified to meet the requirements of a Drug Product (DP). In pharmaceutical manufacturing, it is defined as the reduction of API particle size to less than 10 microns. This process optimizes a drug's biopharmaceutical profile, specifically its solubility, dissolution rate, and delivery efficiency.
The primary driver for micronization is the enhancement of bioavailability for poorly soluble molecules, often categorized as BCS Class II compounds. According to the Noyes-Whitney equation, the dissolution rate of a solute is directly proportional to its surface area. By breaking the material into smaller fragments, micronization exponentially increases the surface area, allowing the API to dissolve faster and improve overall exposure.
Jet Milling: Mechanism and Control
Jet milling is the conventional standard for pharmaceutical micronization due to its robustness and safety. This technique utilizes fluid energy to achieve comminution through an impact breakage mechanism. Compressed gas (usually air or nitrogen) expands through grinding nozzles, accelerating particles into high-velocity collisions with each other rather than the mill walls. Because the gas expansion causes adiabatic cooling (i.e. Joule–Thomson effect) the process is thermally stable and ideal for thermolabile compounds.
Success depends on the precise control of three operating parameters: material feeding rate, feeding pressure, and grinding pressure. Development typically involves a risk assessment of bulk properties (e.g. morphology, flowability) and a Design of Experiments (DoE) to define the Normal Operating Range (NOR) and design space for the API.